Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer

Most prostate cancer patients will progress to a castration-resistant state (CRPC) after androgen ablation therapy and despite the development of new potent anti-androgens, like enzalutamide (ENZ), which prolong survival in CRPC, ENZ-resistance (ENZ(R)) rapidly occurs. Re-activation of the androgen...

Descripción completa

Detalles Bibliográficos
Autores principales: Thaper, Daksh, Vahid, Sepideh, Kaur, Ramandeep, Kumar, Sahil, Nouruzi, Shaghayegh, Bishop, Jennifer L., Johansson, Martin, Zoubeidi, Amina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251893/
https://www.ncbi.nlm.nih.gov/pubmed/30470788
http://dx.doi.org/10.1038/s41598-018-35612-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251893/
https://www.ncbi.nlm.nih.gov/pubmed/30470788
http://dx.doi.org/10.1038/s41598-018-35612-z

Ejemplares similares